BirchBioMed Head Office:
BirchBioMed is a clinical stage pharmaceutical company focused on developing treatments for scarring (fibrosis) and related skin disorders, certain autoimmune diseases, and for organ fibrosis. We hold the exclusive, worldwide, pharmaceutical licenses from the University of British Columbia (“UBC”) for two scientific technologies, FS1/FS2 and AI-001.
In The News
A Leader in strategic drug development, therapeutic options, and market access, Camozzi has successfully led several regulatory interactions, consultations, submissions and approvals, with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), of several pre-INDs and INDs, CTAs and IRBs/ECs, Orphan Drug Applications (ODA) and Designations (ODD), Paediatric Investigational Plans (PIP), successful review approaches, and Marketing Authorisations Applications (MAA).